Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cephalon’s Oncologic Treanda On Track For Q4 NDA Filing

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm's initial goal is non-Hodgkin's lymphoma, but plans are in place for studies in chronic lymphocytic leukemia, mantle cell lymphoma and small-cell lung.

You may also be interested in...



Cephalon On Track To File Treanda For Second Cancer Indication By Year-End

Bendamustine meets both primary endpoints in Phase III for relapsed, rituximab-refractory non-Hodgkin’s lymphoma.

Cephalon On Track To File Treanda For Second Cancer Indication By Year-End

Bendamustine meets both primary endpoints in Phase III for relapsed, rituximab-refractory non-Hodgkin’s lymphoma.

Cephalon To File Treanda For Two Oncology Indications This Year

Company is on track to file chronic lymphocytic leukemia indication in Q3, followed by non-Hodgkin’s lymphoma in Q4.

Related Content

Topics

UsernamePublicRestriction

Register

PS065620

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel